Literature DB >> 9916370

Alzheimer's disease care: costs and potential savings.

J Leon1, C K Cheng, P J Neumann.   

Abstract

A cross-sectional study of 679 Alzheimer's disease patients from thirteen sites in nine states provides a unique opportunity to estimate costs of Alzheimer's disease care by disease stage and care setting and to explore potential areas of cost savings. In 1996 annual costs of caring for patients with mild, moderate, and severe Alzheimer's disease were $18,408, $30,096, and $36,132, respectively. Monthly savings of $2,029 in formal services are possible if disease progression can be slowed. Annual institutional cost savings of $9,132 also are achievable if alternative residential settings are used.

Entities:  

Mesh:

Year:  1998        PMID: 9916370     DOI: 10.1377/hlthaff.17.6.206

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  51 in total

1.  Estimating the long-term cost savings from the treatment of Alzheimer's disease: a modelling approach.

Authors:  P J Neumann
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

Review 2.  The epidemic of Alzheimer's disease. How can we manage the costs?

Authors:  N Johnson; T Davis; N Bosanquet
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

3.  The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach.

Authors:  Grace Wu; Krista L Lanctôt; Nathan Herrmann; Shehnaz Moosa; Paul I Oh
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 4.  The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.

Authors:  Jaclyn Cappell; Nathan Herrmann; Stephen Cornish; Krista L Lanctôt
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

Review 5.  Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease.

Authors:  Qin Nie; Xiao-guang Du; Mei-yu Geng
Journal:  Acta Pharmacol Sin       Date:  2011-04-18       Impact factor: 6.150

Review 6.  A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada.

Authors:  Mark Oremus; S Carolina Aguilar
Journal:  Pharmacoeconomics       Date:  2011-02       Impact factor: 4.981

7.  Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon.

Authors:  Daniel D Christensen
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 8.  Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.

Authors:  Greg L Plosker; Katherine A Lyseng-Williamson
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

9.  Economic valuation and determinants of informal care to people with Alzheimer's disease.

Authors:  Luz María Peña-Longobardo; Juan Oliva-Moreno
Journal:  Eur J Health Econ       Date:  2014-05-07

10.  Sensitivity of nursing home cost comparisons to method of dementia diagnosis ascertainment.

Authors:  Ann L Gruber-Baldini; Bruce Stuart; Ilene H Zuckerman; Van Doren Hsu; Kenneth S Boockvar; Sheryl Zimmerman; Steven Kittner; Charlene C Quinn; J Richard Hebel; Conrad May; Jay Magaziner
Journal:  Int J Alzheimers Dis       Date:  2009-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.